Josephine van Dongen

5 Safety and Tolerability of Human Rotavirus Vaccination 129 Acknowledgements We would like to thank the RIVAR study team, investigators and research nurses of par ticipating hospitals, par ticipants and their parents or guardians for contribution to this study. Funding : The Netherlands Organization for Health Research and Development (836021024), Healthcare Insurers Innovation Foundation, UMC Utrecht and, GlaxoSmithKline Biologicals SA (203108). Role of funding sources : GlaxoSmithKline reviewed a version of the manuscript prior to submission in order to confirm factual accuracy. The authors are solely responsible for final content and interpretation, and share final responsibility for the decision to submit for publication. Declaration of interests : There are no personal or financial relationships relevant to this manuscript, as confirmed by all authors. Trial registration : in Dutch trial registry as NTR5361 www.trialregister.nl